Clinical Laserthermia Systems (CLS) Q4 2024 earnings summary

Executive summary

• 2024 marked a transformative year with net sales more than doubling to SEK 18.8 million, improved gross margin to 52%, and narrowed loss after financial items to SEK -47.9 million from SEK -80.9 million year-over-year.

• Strategic focus shifted to neurosurgery, leveraging partnership with ClearPoint Neuro Inc. and successful commercialization in the U.S.

• Achieved key clinical and regulatory milestones, including ISO certification under MDR and published clinical data in a leading journal.

• Raised SEK 22.4 million through warrant exercise and directed share issue to support strategic transition.

Financial highlights

• Net sales for 2024 reached SEK 18,783,000, up from SEK 8,273,000 year-over-year; Q4 net sales were SEK 4,612,000, up from SEK 4,456,000.

• Operating loss improved to SEK -54,254,000 from SEK -65,933,000 year-over-year; Q4 operating loss was SEK -14,705,000, improved from SEK -20,408,000.

• Loss after financial items narrowed to SEK -47,860,000 from SEK -80,875,000 year-over-year; Q4 loss after financial items was SEK -8,730,000, improved from SEK -25,648,000.

• Basic and diluted EPS improved to SEK -4.3 from SEK -24.1 year-over-year; Q4 EPS was SEK -0.6, up from SEK -3.8.

• Equity ratio increased to 84% from 75% as of December 31, 2024.

Outlook and guidance

• Entering 2025 with a focus on scaling the neurosurgery business, improved financials, and a solid regulatory foundation.

• Targeting positive cash flow by end of 2026 through accelerated commercialization and cost-cutting initiatives.

• Actively seeking strategic long-term investors to support growth objectives.